Related Experiment Videos
Clinical experience with lovastatin.
J A Tobert1, C L Shear, A N Chremos
1Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey.
The American Journal of Cardiology
|March 20, 1990
Summary
Lovastatin demonstrates good tolerability in long-term use, with low rates of adverse events like elevated transaminases and myopathy. Most patients tolerate this cholesterol-lowering drug well.
Area of Science:
- Pharmacology
- Clinical Therapeutics
- Drug Safety
Background:
- Lovastatin is a widely prescribed statin medication for cholesterol management.
- Understanding its long-term tolerability and adverse event profile is crucial for patient safety.
Purpose of the Study:
- To evaluate the tolerability and safety of lovastatin based on long-term therapy data, a large clinical trial, and post-marketing surveillance.
- To identify and quantify adverse events associated with lovastatin use.
Main Methods:
- Analysis of data from an ongoing long-term lovastatin study (744 patients, average 3.6 years).
- Review of preliminary results from a 48-week randomized, double-blind, placebo-controlled trial (8,245 patients).
- Examination of spontaneous adverse event reports from US prescription use.
Main Results:
- In the long-term study, 2.3% of patients withdrew due to adverse events (e.g., elevated transaminases, rash, myopathy).
- In the 48-week trial, myopathy was rare (3 cases), primarily at high doses (40 mg twice daily).
- Withdrawal due to elevated transaminases was low across all lovastatin doses compared to placebo; rare post-marketing events like hypersensitivity and hepatitis were observed.
Conclusions:
- Lovastatin exhibits favorable tolerability in both long-term and short-term use.
- The incidence of significant adverse events, including myopathy and transaminase elevations, is low.
- Post-marketing surveillance confirms the rarity of previously unobserved adverse events, supporting lovastatin's safety profile.